<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106714</url>
  </required_header>
  <id_info>
    <org_study_id>ERC.0002786</org_study_id>
    <secondary_id>62518016.6.1001.0008</secondary_id>
    <secondary_id>R21AI139777</secondary_id>
    <secondary_id>TSA1-2017/720873-0</secondary_id>
    <secondary_id>TSA2-2017/731359-0</secondary_id>
    <secondary_id>206522/Z/17/Z</secondary_id>
    <secondary_id>Convênio 837059/2016</secondary_id>
    <secondary_id>W81XWH-18-2-0040</secondary_id>
    <nct_id>NCT03106714</nct_id>
  </id_info>
  <brief_title>Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil</brief_title>
  <acronym>ZikaBra</acronym>
  <official_title>Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oswaldo Cruz Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Zika infection is a viral disease that is transmitted to humans by the same mosquito that&#xD;
      transmits Dengue and Chikungunya fever. The Zika virus has been found in various body fluids&#xD;
      such as urine, blood and semen, but we do not know how long it persists in these fluids. For&#xD;
      example, parts of the virus were reported to persist in semen after six months of the onset&#xD;
      of symptoms, but we do not know if the virus can stay longer. In this way, we want to&#xD;
      investigate how long the Zika virus can be found in other secretions besides blood and urine.&#xD;
&#xD;
      Study Hypothesis: ZIKV can be shed in human body fluids long after the time of the acute&#xD;
      infection. Persistence of ZIKV in different body fluids may vary due to the influence of&#xD;
      circulating specific ZIKV IgM and IgG, as well as host and environmental factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Little is known about Zika virus (ZIKV) biology and its pathogenesis in humans. ZIKV has been&#xD;
      detected in blood, urine, semen, cerebral spinal fluid, saliva, amniotic fluid, and breast&#xD;
      milk. In most ZIKV infected individuals, the virus is detected in the blood from a several&#xD;
      days to one week after the onset of symptoms and has also been found to persist longer in&#xD;
      urine and semen. Without a more granular understanding of the kinetics of ZIKV infection&#xD;
      across biologic compartments it will be difficult to devise rational measures to prevent the&#xD;
      transmission of the virus.&#xD;
&#xD;
      This will be an observational cohort study of men and women, aged 18 years and above,&#xD;
      including symptomatic participants with positive reverse transcriptase-polymerase chain&#xD;
      reaction (RT-PCR) test in blood and/or urine and their symptomatic or asymptomatic&#xD;
      household/sexual contacts with positive RT-PCR in blood and/or urine. Specimens to be&#xD;
      collected at pre-established intervals and tested for ZIKV RNA by RT-PCR are blood, semen,&#xD;
      vaginal secretions, oral fluid (saliva and crevicular fluid), tears, sweat, urine, rectal&#xD;
      swab, menstrual blood and breast milk (if applicable). Participants will be recruited from&#xD;
      collaborating clinics in selected locations with high population density, high circulation of&#xD;
      the virus, strong community network, and serviced by laboratory facilities with capacity to&#xD;
      perform the necessary tests.&#xD;
&#xD;
      All participants will be followed up for 12 months, to assess detectability at longer time&#xD;
      intervals, reactivation or reinfection. Analyses of antibody response, including circulating&#xD;
      immunoglobulins M and G (IgM and IgG), will be performed in parallel to RT-PCR tests. Plaque&#xD;
      reduction neutralization test will be performed in specimens of participants who are found to&#xD;
      be simultaneously positive for ZIKV and dengue.&#xD;
&#xD;
      Specific analysis will be performed to determine if socio-demographic characteristics,&#xD;
      comorbidities and co-infections influence the persistence of the virus in the body fluids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Actual">June 26, 2020</completion_date>
  <primary_completion_date type="Actual">June 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Persistence and duration of ZIKV</measure>
    <time_frame>12 months of follow-up after ZIKV infection diagnosis</time_frame>
    <description>Persistence and duration of ZIKV in each body fluid in infected symptomatic and asymptomatic participants.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">260</enrollment>
  <condition>Zika Virus</condition>
  <arm_group>
    <arm_group_label>Detectable RT-PCR ZIKV</arm_group_label>
    <description>Men and women aged 18 years and above with diagnosis of ZIKV infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RT-PCR</intervention_name>
    <description>Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids</description>
    <arm_group_label>Detectable RT-PCR ZIKV</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA: whole blood and PBMC Also collected and stored: serum, semen, saliva,&#xD;
      crevicular fluid, urine, vaginal secretions, menstrual blood, rectal swab, tears, sweat, and&#xD;
      breast milk&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a prospective observational cohort study. After signing a screening consent, male&#xD;
        and female potential study participants presenting rash compatible with ZIKV infection in&#xD;
        collaborating clinics will be tested for the presence of ZIKV in blood and urine. The&#xD;
        following day, after providing informed consent for enrolment, those found to be RT-PCR&#xD;
        positive for ZIKV infection, fulfilling all inclusion criteria will be enrolled and subject&#xD;
        of regular collection of body fluids over a period of 12 months according to a&#xD;
        pre-established schedule. Household/sexual contacts will be screened at the reference&#xD;
        centers where the index case was diagnosed or if preferable at their household, and&#xD;
        recruited following the same criteria. The standard care will be provided to all&#xD;
        participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Index Case - Enrolment Inclusion criteria&#xD;
&#xD;
          -  RT-PCR test positive for ZIKV in blood and/or urine specimens&#xD;
&#xD;
          -  Having given consent to provide all body fluid collection, as per protocol&#xD;
&#xD;
        Exclusion criteria RT-PCR test negative for ZIKV in blood and/or urine specimens&#xD;
&#xD;
        Household contacts enrollment (or sexual contacts if index case lives alone) Inclusion&#xD;
        criteria&#xD;
&#xD;
          -  As per index case Exclusion criteria&#xD;
&#xD;
          -  As per index case&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie JN Broutet, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Reproductive Health and Research World Health Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Maria B de Filippis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oswaldo Cruz Foundation (Flavivirus Diagnostic and Reference Laboratory- Rio de Janeiro)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilherme A Calvet, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oswaldo Cruz Foundation (Evandro Chagas National Institute of Infectious Diseases- Rio de Janeiro)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael FO França, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oswaldo Cruz Foundation (Research Centre Aggeu Magalhães- Recife)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcus VG Lacerda, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tropical Medicine Foundation, Manaus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tropical Medicine Foundation</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <zip>69040000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centre Aggeu Magalhães, Oswaldo Cruz Foundation</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50670-420</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evandro Chagas National Institute of Infectious Diseases - Oswaldo Cruz Foundation</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Calvet GA, Kara EO, Giozza SP, Bôtto-Menezes CHA, Gaillard P, de Oliveira Franca RF, de Lacerda MVG, da Costa Castilho M, Brasil P, de Sequeira PC, de Mello MB, Bermudez XPD, Modjarrad K, Meurant R, Landoulsi S, Benzaken AS, de Filippis AMB, Broutet NJN; ZIKABRA Study Team. Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil. BMC Infect Dis. 2018 Jan 22;18(1):49. doi: 10.1186/s12879-018-2965-4.</citation>
    <PMID>29357841</PMID>
  </reference>
  <results_reference>
    <citation>Menezes-Neto A, Castilho MDC, Calvet GA, Kara EO, Bôtto-Menezes CHA, Lacerda MVG, Pereira GFM, Giozza SP, Bermudez XPD, Lima NS, Modjarrad K, Broutet N, de Filippis AMB, Franca RFO; Study Team ZIKABRA. Zika virus RNA excretion in sweat with concomitant detection in other body fluid specimens. Mem Inst Oswaldo Cruz. 2021 Jan 25;115:e200339. doi: 10.1590/0074-02760200339. eCollection 2021.</citation>
    <PMID>33503145</PMID>
  </results_reference>
  <results_reference>
    <citation>Calvet GA, Kara EO, Landoulsi S, Habib N, Bôtto-Menezes CHA, Franca RFO, Neto AM, Castilho MDC, Fernandes TJ, Pereira GF, Giozza SP, Bermúdez XPD, Modjarrad K, Lima N, Brasil P, de Lacerda MVG, de Filippis AMB, Broutet NJN; ZIKABRA Study Team. Cohort profile: Study on Zika virus infection in Brazil (ZIKABRA study). PLoS One. 2021 Jan 5;16(1):e0244981. doi: 10.1371/journal.pone.0244981. eCollection 2021.</citation>
    <PMID>33400705</PMID>
  </results_reference>
  <results_reference>
    <citation>Bôtto-Menezes CHA, Neto AM, Calvet GA, Kara EO, Lacerda MVG, Castilho MDC, Ströher U, Antunes de Brito CA, Modjarrad K, Broutet N, Brasil P, Bispo de Filippis AM, Franca RFO; ZIKABRA Study Team. Zika Virus in Rectal Swab Samples. Emerg Infect Dis. 2019 May;25(5):951-954. doi: 10.3201/eid2505.180904.</citation>
    <PMID>31002058</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>February 27, 2021</last_update_submitted>
  <last_update_submitted_qc>February 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oswaldo Cruz Foundation</investigator_affiliation>
    <investigator_full_name>Guilherme Amaral Calvet</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>persistence</keyword>
  <keyword>body fluids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

